2010 annual report

1 P A R E S E A R C H F O U N D AT I O N

Research for Life.

2

Contents 3 PA Research Foundation Overview

4 Chairman’s Report

5 Board Members

7 Research Committee

8 Corporate Governance

9 Research 2009 / 2010

17 Fundraising in the Community

26 Our Supporters

28 Our Sponsors

29 Financial Report


PA Research Foundation Overview

Research for life

The PA Research Foundation raises funds for groundbreaking, lifesaving research—to develop better diagnoses, treatments and preventions for some of Australia’s biggest health challenges. This research reduces human suffering and enhances quality of life; it reduces the burden on already stretched health care budgets, and fosters Australian ingenuity and industry.

The Foundation was established in 1984 to raise funds for world class health and medical research at the Princess Alexandra Hospital—Queensland’s leading research hospital and our largest clinical trials centre. “Gardasil” and the “Brisbane Technique” are just two familiar entries in a long list of significant achievements.

All research funded by the Foundation goes through a rigorous selection process to ensure it is of genuine scientific merit, and does not replicate any other research anywhere in the world. All funds raised therefore contribute to the highest calibre research, to tackle some of the most challenging health problems facing us as a nation …

Thanks to the donations of individuals, families, communities and businesses—millions of dollars have been raised—this research has improved the lives of literally millions of people around the world.

Substantial sums considering all funds are generated by the general public, the business community, private practice trust funds, fundraising events, bequests and the many patients and families who have benefited from medical treatment provided by the PA Hospital.

Our cervical cancer vaccine the first cancer vaccine in the world, is major milestone in the fight against cancer, and one of the greatest medical breakthroughs since penicillin.

These funds directly benefit the PA’s groundbreaking research projects in areas such as cervical cancer, prostate cancer, skin cancer, leukemia, breast cancer, heart disease, immunology, kidney disease, diabetes, liver disease, transplantation and arthritis.

Investing in smart thinking

This is not just an investment in the future health and wellbeing of our families and communities; it is also an investment in Australian industry and ingenuity. In the words of Professor Ian Frazer: “As individuals and as a nation, we need to value ideas. The solution to many of today’s challenges will start with an idea and be driven by a commitment to find that solution.”

One breakthrough benefits many. And every donation takes us a step closer to the next one. In the next decade, the Foundation aims to build on its considerable achievements to date, and advance the PA Hospital’s world leading, life saving research. The new Translational Research Institute is now in development—the only facility of its kind in the Southern Hemisphere, it will house the 800-plus people who make up our research community.

The PA Research Foundation would like to take this opportunity to thank the many individuals, families and businesses who have supported our vital work in the past. We look forward to working with you further in the future, as we continue to foster research for life.

42 0 1 0 A N N U A L R E P O R T

Each year provides the Foundation with new opportunities to fund exceptional research projects proposed by the many talented and dedicated clinicians, scientists, nursing and allied health professionals on the Princess Alexandra Hospital campus.

The challenge is of course to find the dollars to support as many projects as poss- ible and with a global financial crisis to contend with this has been a difficult task.

Despite this we have managed to fund $1,146,000 of new research on the campus. This includes ten clinical research grants totalling $750,000 from the PA Hospital Private Practice Trust Fund.

The Foundation’s fundraising efforts have generated $1,193,600. I would like to make mention of the exceptional effort of our dedicated staff in the Foundation office to our general fundraising efforts and special events. The Great Brisbane Duck Race is generating increasing interest and support for the Foundation and is now well and truly etched into the Brisbane events calendar.

To each and every one of our donors, sincere thanks and appreciation for your continued support of the great work and achievements of our research community

To our growing team of corporate partners and sponsors, thank you on behalf of the Foundation for your participation in our community fundraising activities.

In conclusion, I would like to thank my fellow Board members for their time, dedication and guidance throughout the year. I would also like to welcome to the Board Mr Cameron Buchanan and Mr Les Watson, Chair of the Princess Alexandra Hospital Health Community Council.

I look forward to further growth and development of the Foundation’s fundraising activities in the coming year, with increasing support for medical research on the PA Hospital campus.

Robert Bowen

Chairman

Chairman’s Report


Board Members

The Board Members during the year ended 30 June 2010.

Mr Robert Bowen CHAIRMAN

Mr William Deutrom OAM DEPUTY CHAIRMAN

Mr Les Watson CHAIRMAN DISTRICT HEALTH COMMUNITY COUNCIL

Mr Andrew Griffiths Mr Michael Wille OAM Professor Ian Frazer

Dr Richard Ashby AM Mr Richard Bowly Mr Gareth Evans RESIGNED 04.09.2009

62 0 1 0 A N N U A L R E P O R T

Mr Robert Vines

Mr Michael Back HONORARY SOLICITOR

BA (Hons.) LLB (Hons.) Managing Partner, Freehills

Mr Cameron Buchanan

Mr Phillip Sciacca HONORARY ACCOUNTANT

B. Bus, CA Partner, Sciacca & Co., Chartered Accountant

Mrs Linda Lavarch RESIGNED 21.01.2010

Professor John Prins RESIGNED 27.07.2010

Professor David Thiele AO

Ms Heather Tyrrell COMPANY SECRETARY

Q Health Grad Cert Management Manager Governance and District Executive Management Services, Queensland Health


Research Committee

Associate Professor Mark Smithers ACTING CHAIR

Professor Len Gray

Professor Leanne Aitken

Professor John UphamProfessor Robert Tindle

Nicholas Allen Chief Executive Officer

Simone Plunkett Manager – Marketing Communication

Jenny Cotter Office Manager

Kerstin Petrick Accounts and Administration

Doctor Maree Ferguson

PA Research Foundation Staff

82 0 1 0 A N N U A L R E P O R T

Corporate Governance

The PA Research Foundation is a

statutory body incorporated under the

Hospital Foundations Act 1982 (QLD).

As a statutory body the Foundation is

subject to the provisions of the Financial

Accountability Act 2009 (QLD). The

Foundation is audited annually by external

auditors representing the Queensland

Audit Office and the Auditor General.

The Foundation is governed by a voluntary

Board which is responsible for the overall

strategic direction of the Foundation,

overseeing its operations and establishing

policies and procedures.

The Foundation is endorsed by the

Australian Taxation Office as an Income

Tax Exempt Charity (ITEC) and is a

Deductible Gift Recipient (DGR) under the

Income Tax Assessment Act 1997 (Cth).

It is endorsed for GST concessions under

A New Tax System (Goods and Services

Tax) Act 1999 (Cth) and it is exempted

under the Fringe Benefits Tax Assessment

Act 1986 (Cth).

The Role of the Board

The Board and management have been

entrusted with the responsibility of

ensuring that monies provided by donors,

sponsors and the general public are

effectively and efficiently managed.

Board members serve in a voluntary

capacity and therefore receive no

fees for their services on the Board or

Committees.

The role of the Board includes:

accountability to our stakeholders

and external regulators

the external environment

financial, social and corporate

governance responsibilities

developing, examining and approving

strategies, policies, plans and budgets

presence of adequate risk management

controls and reporting procedures

ethically, responsibly and openly.

Executive Management

The Board delegates responsibility for

implementing strategies approved by the

Board and day-to-day management to

the Chief Executive Officer, who in turn is

accountable to the Board.


Research 2010

In 2009 financial year, the PA Research

Foundation was proud to have awarded

over $750,000 dollars for clinical

research.

The Princess Alexandra Hospital is one of

Australia’s leading teaching and research

hospitals, with a strong research culture

and active programs in basic science and

clinical research.

It undertakes health research programs

independently and with affiliated

universities including the University of

Queensland, Griffith University and the

Queensland University of Technology.

Each year the Foundation invites

applications from health researchers

on the campus. Applications are then

assessed by the Research Committee,

an independent team of qualified medical

professionals, and awarded based on

merit and funds available.

The philosophy of awarding research

grants is to:

successful in securing competitive

funding.

campus.

in the early stage of their research

career and,

and group work which is a major

strength of the PA research

environment.

All applications are based on scientific

quality, relative to the field of research,

track record of the researcher or research

group and innovation.

Funding Schemes

Appointment Grant – for new

appointees to the PAH campus

who have an established track record

in research.

Practice Trust Fund Research

Support Grants – these grants are

supported by funds from the hospitals

private practitioners and administered

through the PA Research Foundation.

These grants are exclusively granted to

clinician researchers.

Allied Health Grants – for Allied Health

professionals, Registered Nurses,

Clinical Medical and Scientific trainees.

Grants - Established researchers

seeking funds for new collaboration

or clinical translation which may lead

to further external funding.

1 02 0 1 0 A N N U A L R E P O R T

Private Practice Trust Fund Grants Awarded

Emergency Medicine and

Geriatric Rehabilitation Unit

Project Title Identifying brittle discharges

from the ED: A prospective study.

Chief Investigator Professor Len Gray,

Director, Centre for Research in Research

in Geriatric Medicine

Associated investigators Dr Ellen

Burkett, Dr Salih Salih, Dr Paul Varghese,

RN Bonnie Pimm, RN Julia Ritchie and

Dr Prabha Lakhan.

Introduction The aim of this project was

to identify predictors of poor outcomes

for patients discharged from emergency

departments of two hospitals in Brisbane,

who are aged 75 years and older, and

residing in low level care supported

accommodation or in private homes.

Study progress update Ethical approval

to conduct the study was obtained

from the Princess Alexandra Human

Research and Ethics Committee; Mater

Health Services Human Research and

Ethics Committee and The University of

Queensland Medical Research Ethics

Committee.

One hundred and thirty four patients

discharged from the Princess Alexandra

Hospital and 152 patients discharged

from the Mater Adult Hospital emergency

departments during the recruitment

period were included. Written consent

was obtained from the patient or the

next of kin. The 286 patients recruited in

the study is less than the target of 500

patients, mainly because of insufficient

number of patients who presented to

the emergency departments during the

recruitment period and who could provide

written consent.

Data collection was completed earlier in

2010, and data assembly and analysis are

now in progress.

The study will be concluded before the

end of 2010.

Importantly, this project has stimulated an

international collaborative effort around

quality care in the ED. We are now

leading a multi-site international study,

wherein EDs in Belgium (3), Canada (4),

Germany (1), India (1) and Sweden (2)

are collecting similar data to our study.

Together we will have assembled a study

with over 2000 subjects to address similar

questions to those posed in the original

PAH study. Results are anticipated in

early 2011.

Further, it has resulted in the development

of a large study to develop Quality

Indicators for the care of older patients

in the emergency department, which

has been submitted for funding to the

Queensland Emergency Department

Research Foundation. It has also

attracted a PhD student who is studying

the management of cognitive impairment

in the emergency department.

1 1 P A R E S E A R C H F O U N D AT I O N

Research 2010

Infection Management Services

Project Title Ethanol lock therapy for

the prevention of tunnelled intravenous

catheter-associated bacteraemia.

Chief Investigator Dr Jennifer Broom

Associated Investigators Professor

David Johnson, Dr Geoffrey Playford, Dr

Peter Mollee, Dr Nick Graves, Associate

Professor Michael Whitby, Associate

Professor David Looke, Dr Joan Faogali,

Dr Carmel Hawley, Dr WWendy Munckhof,

Dr Nicky Isbel, Dr Scott Campbell, Dr

David Mudge and Dr Sridevi Govindarajulu.

Introduction Tunnelled central venous

catheters have an essential role in

providing temporary venous access for

haemodialysis in patients with end stage

renal failure (ESRF). Their use is limited

by the occurrence of catheter related

infections which confer significant patient

morbidity and mortality. Approaches to

reducing catheter associated infection

include both external approaches and

luminal lock techniques. Lock solutions

that have been assessed include antibiotic

and citrate locks. Antibiotic locks have

had limited success and may result in the

promotion of antimicrobial resistance or

toxicity associated with long term antibiotic

exposure.

Sodium citrate locks are associated

with an increased incidence of catheter

thrombosis without clear evidence of

benefit in the prevention of infection.

Ethanol is attractive as a lock solution as

it is bactericidal by protein denaturation

(eliminating concerns about the

development of antimicrobial resistance),

has a broad range of antimicrobial activity,

is cheap and metabolised by humans, and

does not damage catheters by prolonged

exposure.

This randomised controlled trial assessed

the efficacy of a 48 hour 70% ethanol

lock once per week vs standard heparin

locks in patients undergoing haemodialysis

via a tunnelled catheter. Patients with

prevalent and incident catheters were

randomised 1:1 to ethanol vs heparin

locks. Patients receiving ethanol lock

therapy received standard heparin locks

between other dialysis days. Planned

recruitment was for 112 patients (56 in

each group). The trial was ceased after 47

patients were recruited due to improved

access to permanent dialysis solutions

and a consequent significant reduction

in recruitment. A total of 991 catheter

days were observed in 24 patients in the

ethanol group, and 1320 catheter days in

23 patients in the heparin group. Catheter

related blood stream infections did not

occur in patients in the ethanol group, but

occurred in 4 patients (3/1000 catheter

days) in the heparin group.

Other adverse events requiring catheter

removal (including flow related problems)

occurred in 7 patients (7/1000 catheter

days) in the ethanol arm and in 8 patients

(6/1000 catheter days) in the heparin

group. Catheter blockage and thrombosis

was a concern prior to the trial, as patients

in the ethanol group would not have

heparin in situ for 48 hours per week.

Flow problems occurred at a rate of 4 vs

2 per 1000 catheter days in the ethanol

and heparin groups respectively. Venous

thrombosis did not occur in either group.

Private Practice Trust Fund Grants Awarded

1 22 0 1 0 A N N U A L R E P O R T

Participants Of a planned 112 patients,

47 patients were recruited from October

2006 to July 2010. The accessibility of

long term vascular access at the Princess

Alexandra improved dramatically during

the study period, reducing the rate of

recruitment to the study dramatically.

Further multi centre studies are required

to recruit higher participant numbers.

Of 47 patients, 24 were randomised to

the ethanol lock arm of the trial and 23

were in the heparin lock arm. There were

no significant demographic differences

between the two groups.

Outcomes

Catheter complications (non infective)

A total of 991 catheter days were

observed in the ethanol lock arm and

1320 in the heparin lock arm. The

median life of the catheter in each group

was X for the ethanol lock arm and X for

the heparin arm. Catheter complications

resulting in removal of the catheter were

documented for 7 patients on the ethanol

arm and 8 patients in the heparin arm

(7 vs 6 per 1000 catheter days). Of

these complications, 4 patients had flow

difficulties in the ethanol lock arm and 2

patients had flow difficulties in the heparin

lock arm (4 vs 2 per 1000 catheter days).

Mechanical dysfunction occurred in 2

patients on the ethanol arm and 1 patient

on the heparin arm (catheter fell out).

Catheter associated infections

Catheter related blood stream infections

did not occur in any patients on the

ethanol arm, and occurred in 3 patients

on the heparin arm (0 vs 3 per 1000

catheter days). The organisms isolated

in the 3 patients on the heparin arm

who had CR-BSI were: Staphylococcus

aureus, Enterobacter cloacae, and

Staphylococcus hominis. One patient

met criteria for definite catheter related

blood stream infection (patient 2, isolating

Staphylococcus aureus from both blood

cultures and catheter tip culture). The

other two patients met criteria for probable

CR-BSI. CR-BSIs occurred after 78, 134,

and 135 days on the trial. All 3 catheters

were removed. One exit site infection from

which Methicillin resistant Staphylococcus

aureus (MRSA) was cultured from an exit

site swab occurred in the ethanol arm

resulting in removal of the catheter. No

exit site infections were documented in

the heparin arm. Tunnel infections did not

occur in either arm.


Nutrition and Dietetics Department

Project Title Nutrition as medication for

hospitalised patients with malnutrition in a

geriatric and rehabilitation unit (GARU).

Chief Investigator Dr Maree Ferguson,

Director, Nutrition & Dietetics Department

Associated Investigators Dr Angela

Vivanti, Dr Paul Varghese, Hament Amin,

Philip Dickson and Professor Sandra

Capra.

Introduction Malnutrition is a common

problem in hospitals with reported

prevalence ranging from 16% to 40%.

Given the high malnutrition prevalence

in GARU, the study aimed to determine

the most effective method for providing

nutrition support to this group.

Study Progress Update Forty-five

patients with malnutrition SGA B or

C (89% SGA B) from GARU were

recruited into two nutrition support

interventions: conventional supplements

(n=25), or Medpass (n=20) (60ml two

calorie supplement delivered four times

daily at medication rounds). Three

day food records evaluated outcomes

after two weeks of intervention. No

significant differences existed in baseline

characteristics between the two groups.

Nutritional intake (Medpass 6398

± 1923kJ, 71.5 ± 20.9g protein;

supplements 5557 ± 2004kJ, 60.5

± 19.7g ) of both groups significantly

improved (p<0.001) in energy (Medpass

7316 ± 1614kJ, supplements 6698 ±

1790 kJ) and protein content (Medpass

78.3g ± 18.5, supplements 72.5g ±

16.2) with nutritional support.

There were significant improvements in

the Medpass group over conventional

supplements for protein intake (16g±8.0,

versus 11.1g±5.9, p<0.05); patient

satisfaction (ease of consumption) 100%

satisfied with Medpass, 67% satisfied

with supplements (p=0.01); and increased

quality of life (Medpass 64.5 ± 17.7,

supplements 53 ± 19.6, p=0.015). After

two weeks, consumption of conventional

supplements reduced by ~10% whereas

Medpass remained stable (p<0.01.

Both nutrition support methods were

beneficial; with Medpass showing greater

improvements in a range of clinical and

patient-centred outcomes. Results show

Medpass is well received and a potentially

cost effective therapy for geriatric and

rehabilitation patients with malnutrition.

Research 2010 Private Practice Trust Fund Grants Awarded

1 42 0 0 9 A N N U A L R E P O R T

Department of Renal Medicine

Project Title The role of

25-hydroxyvitamin D deficiency in

promoting insulin resistance and inflam-

mation in patients with Chronic Kidney

Disease: A randomised controlled trial.

Chief Investigator A/Prof Nicole Isbel

and Dr William Petchey

Associated Investigators Dr Emma

Duncan,Dr Ingrid Hickman,Dr Liza Phillips,

Dr Carmel Hawley,Prof Johannes Prins,

Prof David Johnson, Dr Scott Campbell,

Dr David Mudge and Carolyn Van Eps.

Introduction To provide prospective data

regarding the novel use of cholecalciferol,

a safe and effective vitamins D supp-

lement, to ameliorate insulin resistance

in patients with CKD. In addition, effects

on inflammatory burden, bone-adipokine

metabolism and vascular function will also

be assessed.

Objectives

1. Assess serum vitamin D levels in

patients with CKD stage 3, and assess

for independent association with insulin

resistance and a pro-inflammatory state.

2. Supplement patients with vitamin

D3 (cholecalciferol) for 6 months to

assess safety, tolerability, and efficacy

at correcting vitamin D deficiency and

ameliorating insulin resistance.

3. Assess changes in circulating

inflammatory burden (peripheral blood

mononuclear cell nuclear transcription

factor activity and serum cytokine profile)

in response to vitamin D therapy.

4. Assess the effect of cholecalciferol

supplementation on serum osteocalcin

and adiponectin concentrations, in relation

to changes in insulin sensitivity.

5. Monitor changes in endothelial function

and vascular structure with vitamin D

intervention, in relation to the metabolic

parameters detailed above.

6. Examine the relationship between fat

mass and the ability to increment with

vitamin D therapy.

Methodology All patients aged 18 or

over meeting the inclusion/exclusion

criteria attending Princess Alexandra

Hospital Nephrology department will

be invited to participate. Patients will

be randomised to either vitamin D

(cholecalciferol 50mcg/day) or placebo

for six months, with baseline and end-of-

study testing. Outcome measures to be

assessed include:

euglycaemic clamp)

in relation to metabolic challenge

(indirect calorimetry)

nuclear transcription factor activity,

serum cytokines IL-1 , IL-6, TNF ,

CRP)

osteocalcin, catabolic/anabolic bone

markers, adiponectin)

wave velocity/analysis and flow

mediated dilatation)

mass (total body DXA scan)

Study Progress Update The project

received ethical approval in July 2009,

and a 0.2 FTE research nurse was


appointed to post. Following a slow

initial recruitment process the inclusion/

exclusion criteria was revised to allow

greater representation of the general

nephrology cohort in the population

approached. This amendment was

approved in September 2009. Since

that time recruitment has been steady,

and to date 26 patients have been

recruited to the randomised component

of the study (target: 38, allowing for

20% drop-out with correction factor 1/

(1-drop out rate)2). Of these, 23 are

thus far randomised. One has been lost

to follow up, and two were excluded due

to diagnosis of diabetes at baseline, the

treatment of which contravenes exclusion

criteria. 13 patients are expected to enter

the observational arm of the study with

frank vitamin D deficiency, however this

level of hypovitaminosis has not yet been

encountered; partly due to recruitment

over the summer months. Allocation

to this arm of the study is expected

throughout Autumn/Winter 2010.

Two publications have arisen from the

study thus far (both the literature review

and study protocol) and Dr Petchey

was successful at confirmation of PhD

candidature, with the current study being

the central component of his proposed

thesis. Dr Petchey has also given guest

presentations on the pleiotropic role of

vitamin D, including work from the current

study at the international annual scientific

meeting (ASM) of the Joint Faculty of

Intensive Care Medicine (Australia and

New Zealand) 2009. Further abstracts

have been submitted to the ANZ Society

of Nephrology ASM 2010, with further

work due for submission later in the

year. The work has also been selected

for a competitive, peer-reviewed research

award in 2009 (Nephrology Research

Award, Roche Pty Ltd), for which the

research proposal was highly commended.

Preliminary Observations Recruiting for

this study has already demonstrated that

low vitamin D levels are very common in

people with kidney disease, with over half

of patients having insufficient quantities

of vitamin D in the blood despite the high

sun exposure in sub-tropical Queensland.

Risk factors for this include having

diabetes, taking less physical exercise,

and being overweight. In associated work

we have also observed that lower vitamin

D levels are related to abnormal sugar-

handling in the blood (“pre-diabetes”), and

worse cardio-respiratory fitness, both of

which are risks for developing diabetes

and heart disease later on. Finally, our

initial data would indicate that people

with kidney problems burn fat slower to

provide energy for the body when fasted,

and when fed are unable to use new fuel

(energy in food) as effectively as people

without kidney disease. We hope that

supplementation with vitamin D will go

some way to rectifying these adverse

metabolic problems.

Research 2010 Private Practice Trust Fund Grants Awarded

1 62 0 0 9 A N N U A L R E P O R T

Rheumatology

Project Title A dendritic cell vaccine

to suppress the immune response to

citrullinated antigen in rheumatoid arthritis.

Chief Investigator Professor Ranjeny

Thomas

Associated Investigators Phillip Vecchio,

Brendan O’Sullivan, Marion Brunck and

Helen Pahau.

Introduction In this current application

we sought funding to support the above

clinical trial of modified dendritic cells and

citrullinated autoantigenic peptides in

rheumatoid arthritis (known as Rheumavax).

The primary aims are to demonstrate

in a phase I clinical trial of Rheumavax

administered to patients with rheumatoid

arthritis taking disease-modifying drugs for

their disease, (1) safety and (2) capacity

to suppress the immune response to

citrullinated autoantigen.

1. Safety will be evaluated by clinical

assessment and laboratory test monitoring

in the Rheumavax groups compared

with the control group, as measured

by hematological, biochemical and lipid

profile, autoantibodies, and measures of

inflammation carried out at intervals, over

6 months.

2. Suppression of immunity will be assessed

in the Rheumavax groups, compared with

a control group, by peripheral blood T cell

proliferative and T cell cytokine responses

to citrullinated-peptides, control peptides

and tetanus toxoid antigen for 6 months

after delivery of Rheumavax. The titre and

isotype of anti-CCP (citrulline-specific

autoantibodies) will also be measured over

6 months.

The secondary aim is efficacy. We

will determine whether Rheumavax

administered to patients with rheumatoid

arthritis influences disease activity, as

measured by the health assessment

questionnaire, disease activity and American

College of Rheumatology scores, and hand

radiographs.

Study Progress Update The trial

commenced in November 2009 and

clinical data and blood samples have

been collected from the control group

of 9 patients and the second group of 9

patients who received 1 million dendritic

cells. We are currently treating the third

group of 9 patients with 5 million dendritic

cells and samples are being collected for

the analysis of T cell responses. Safety

data demonstrate that the therapy is well

tolerated, with only minor and infrequent

adverse events. Clinical data collection will

be ongoing until early 2011. We anticipate

carrying out T cell analyses from stored

samples towards the beginning of 2011.

In preliminary analysis, we measured

peripheral blood T cell responses to

9-13mer native and citrullinated peptides

derived from type II collagen or vimentin

based on their predicted binding to

the HLA shared epitope (SE), in SE+

RA patients with citrullinated-peptide

autoantibodies (ACPA), SE- RA patients,

and SE+ healthy controls. Peripheral

blood mononuclear cells were incubated

without or with 30ug/ml native or

citrullinated vimentin or collagen type II for

5 days. Positive control antigens were

DR4-restricted influenza hemagglutinin

peptide, and tetanus toxoid. Proliferative

and cytokine responses were measured.

T cell proliferative and IL-17 responses

to citrullinated and corresponding native

autoantigens were observed in SE+ACPA+

RA patients but not SE+ healthy controls

or SE- RA patients. IL-17 was secreted by

peripheral T cells of RA patients at similar

levels in response to autoantigenic peptides

and tetanus toxoid.


Fundraising in the Community

The Great Brisbane Duck Race 2009

Over 16,500 rubber ducks flocked to

the Brisbane River on Saturday 26th

September 2009 for the PA Research

Foundations signature annual event

The Great Brisbane Duck Race in aid of

cancer research.

Hundreds of competitors and spectators

lined the shores of South Bank Park-

lands to cheer on their duck and have a

quacking good time. Pre-race jitters were

a thing of the past as the ducks all fluffed

and flexed their feathers before the official

start of the race.

It was a competitive race from the

moment the starter’s horn was blown as

ducks not only battled each other but also

Mother Nature with windy conditions and

downward tides to contend with. But the

100m course upstream was no match for

the winning duck who broke away from

the flock early and managed to hold the

lead through to the finish line.

This year we congratulate Duck number

8179 who was by far the strongest of the

fleet. The lucky duck to win the first prize,

a Toyota Yaris, courtesy of this year’s new

Presenting Sponsor Sci- Fleet Toyota was

Louise Edgley from Wynnum who went in

the charity race with the team from Unidel

Group. Unidel GIS Co-ordinator Gary

Hutton bought the ducks online for his

team with Louise being the lucky recipient

of the winning duck.

“I couldn’t believe it when I got the call

that I had won the car. Unidel like to get

behind community fund-raisers and we

thought The Great Brisbane Duck Race

fitted perfectly with our philosophies. This

is such a wonderful cause and to know

we are contributing to cancer research

makes it that much more special.”

Corporate Duck Race Challenge

For the first time a Corporate Duck Race

was held as the curtain raiser for the main

event. The event attracted over

20 corporates who bought along their

huge modified painted ducks to battle

it out over the 100 metre course for

bragging rights with Results Web Design

taking out the title.

The objective was to be the first duck to

cross the finish line over the 100m course

on the Brisbane River and win the naming

rights to next years race however the rules

were different for the corporate race –

there were none!

This left many businesses and their

technicians pondering the question: what

type of duck would it take to win the

Corporate Duck Race? A feathery duck?

A glittery duck? A surfing duck? Plucka

Duck?

Weeks before the inaugural Corporate

Duck Race entrants all over Brisbane

were modifying, painting, and gluing their

ducks in the hope of being the first ever

winner of the race.

As the race day dawned preparations

were finally in place and entrants

proudly showed off their designs to their

competition. There were gasps and ooh’s

as some of the ducks resembled entrants

into the power boats championships

Waterway Constructions Management

impressed the crowds with their one

1 82 0 1 0 A N N U A L R E P O R T

Thank you to everyone who

adopted a duck!

metre design of a speed boat with the

duck sitting on top. Pipe Networks had

front mounted skies and a keel fitted to

their duck along with a wireless camera

hooked up to a video capture card so it

can be piloted using a laptop.

Then there were ducks with shower caps,

ducks with bowties, ducks on surfboards

and ducks with rubber floaties. The

competition was tough and there were

certainly a few ruffled feathers.

It was a slow start for some who never

quite made it off the start line and a great

start for others but unfortunately some

quacked it half way through the race.

The eventual winner was Results Web

Designs from Oxford Street, Bulimba

Director, Scott McNaught said it took over

ten hours to construct their duck. “Our

first design didn’t do well after we took

it for a test run in the Brisbane River

so we spent the morning of the duck

race looking for replacement parts. We

eventually got it finished at midday in time

to get to the race,” Mr McNaught said.

“We are proud to be associated with

this event knowing that all funds raised

are going towards cancer research. I

encourage all businesses in and around

Brisbane to be part of this event next year.

Not only is it a fun day but you will be

making a difference to people’s lives now

and into the future.”

Because of all the support, the PA

Research Foundation raised over

$70,000 from the duck race with all

proceeds going towards cancer research

on the PA Hospital Campus.

The success of this year’s Great Brisbane

Duck Race could not have been achieved

without the PA Research Foundation’s

loyal supporters, the generosity of the

Brisbane community and the wonderful

sponsors with a special thanks to

Sci-Fleet Toyota, Quest Community

Newspapers, Waterway Constructions,

Bowen Tug & Barge, B105 and Channel

Nine.



Ladies Luncheon

The Foundation was the beneficiary to

this year’s Inaugural Ladies Luncheon

organised by the wonderful Ms Julie Vines,

wife of Bob Wines PARF Board member

Julie has been hosting annual charity

lunches over the past decade and this

year wanted to raise funds through the

lunch for medical research.

The Ladies Luncheon for over 120 ladies

was hosted at Baguettes Restaurant in

Hamilton. Julie ensured all costs of the

lunch and prizes were donated so that the

ticket price went directly to where it was

needed most - medical research.

The lunch was hosted by the lovely

Marie-Louise Theile. With guest speaker

Professor Ian Frazer who kindly gave his

time to the delight of the 120 women who

made up the function. The Foundation

was the very happy recipients of the

Luncheons fundraising efforts of $24,000.

A very special thank you to Julie and all

the businesses that helped make this

luncheon a success. Thank you to:

Running for Research

Princess Alexandra Hospital staff raised

$6,500 for cancer research in the annual

Smiddy’s Fun Run.

Over 250 people participated in the race

on 10 November, which is held annually

in memory of late PAH physiotherapist

Adam Smiddy.

The fun run, now in its fourth year has

been growing in numbers and popularity

and has become somewhat of a tradition

attracting hundreds of competitive runners

each year.

The winning male raced home in 16.36

minutes and the first female crossed the

finish line in 18.36 minutes.

The funds were put towards the purchase

of a Vivascope Imager for PAH’s

Dermatology Research Centre for skin

cancer research.

The Vivascope is a non-invasive

imaging tool which allows doctors to

see microscopic changes in skin tissue,

so they can detect the early onset of

melanomas. It can also determine the size,

location and shape of cancer cells.

A special thanks to the PA Physiotherapy

Department and to all the sponsors:

The Greek Yoghurt Company, Intraining,

PA Lifestyle Program, Bakers Delight,

Buranda Fresh, Mick’s Nut Store, Emma

and Tom’s Life Juice and Starbucks.

2 02 0 1 0 A N N U A L R E P O R T

wines and bubbly,

2 nights accommodation at Zanziba

Apartments in Mooloolaba,

hour sunset cruise on the Navigator

42 Ft.,

gift voucher,

Hermitage, Magnum of bubbly and

Magnum of Award Winning Red,

Thalgos pack and Stephanie’s Spa

Retreat package,

2 $100 gift vouchers,

voucher,

gift voucher, and

whitening session.

Heart to Heart Beach Walk

Family’s heart felt fundraiser ...

The 8km walk from the Spit to

Broadbeach on Saturday 10 November

was in memory of Raymond Penny who

tragically lost his life at the young age of

26 while surfing. Ray suffered from an

undiagnosed heart condition.

In death Raymond Penny saved both

his mother and his sisters’ lives and six

years on he may be saving many more.

Raymond passed away on November

8, 2003, after suffering a heart attack

while surfing. It was discovered he had a

rare heart disease, CPTV, that can cause

blackouts and instant heart failure.

When his mother Susan and his sister

Sharron went for tests it was found

they, too, had CPTV. They now have

defibrillators that regulate their heartbeat

On Saturday, they both took part in the

inaugural Heart to Heart Beach Walk to

honour Raymond’s memory and raise

awareness of heart disease.

‘‘It was quite overwhelming to see the

number of people who turned out for the

walk’’ said Ms Jones. ‘‘All of the support

is really great. ‘When I was growing up I

thought only old people could suffer heart

disease but young people suffer it too.’’

More than 50 people walked to raise

awareness and funds for the PA Research

Foundation. The 8km walk started at The

Spit, one of Raymond’s favourite surfing

spots on the Gold Coast. The group was

dressed in red for heart disease and

walked along the beach to Kurrawa Surf

Club at Broadbeach.

A special thank you to Susan Jones and

all participants and supporters who helped

raise awareness of heart disease and

funds for cardiac researchers. And thank

you to Super Butchers for providing the meat

for the barbeque at the end of the walk.



PA Shave

PAH staff shave to support local research

at the Princess Alexandra Hospital.

PA Staff showed their generosity by

raising nearly $3,000 at the inaugural ‘PA

Shave’ event this month.

It was out with the scissors and in with

the donations on Wednesday 10 March as

a number of staff members shaved their

hair to raise funds for the PA Research

Foundation.

Anne-Marie Perkins provided commentary

for the event, while hair-cutting duties

were performed by the qualified stylists of

Bossy Hair Buranda. Over 8 brave staff

members took on the shave challenge and

those who weren’t quite brave enough

to lose all of their locks supported the

cause by having their hair coloured. The

event, held in the hospital’s main foyer,

attracted a large audience keen to see

their colleagues as they’d never seen

them before.

The ‘PA Shave’ is intended to become

an annual event on the foundation’s

fundraising calendar. All money raised at

the event will go towards cancer, heart

disease and diabetes research conducted

on the Princess Alexandra Hospital

campus.

Special thanks go to the event’s sponsors,

including Bossy Hair Centro Buranda,

Heinz Meats South Brisbane, Luv A

Coffee Buranda, Bankwest, CUA, Terry

White Chemists, Centro Buranda and

Starbucks.

Hotel Care Month

PA Toasts Queensland Hotels.

September was a month to raise your glass

and make a “shout” for good health as the

Queensland hotel industry raised more than

$210,000 for medical research.

More than 250 hotels and bottle shops

across the state rallied together to raise

funds for the PA Research Foundation and

Mater Foundation to support health research.

Since QHA Hotel Care began six years

ago they have raised over ONE MILLION

DOLLARS.

Every cent donated by the hotels, bottle

shops and their patrons has gone directly

to the cause – to improve the health of the

community throughout Queensland.

A very special thanks to Queensland

Hotels Association Justin O’Connor, Bob

Singleton, Keri Crompton, the Sponsors and

all the participating hotels and bottle shops

throughout Queensland.

2 22 0 1 0 A N N U A L R E P O R T

PA’s Greatest Morning Tea

Ready, steady cook!

Staff join in morning teas to raise over

$6000 for cancer research.

Princess Alexandra Hospital’s Andrea

joined fellow occupational therapists Laura

and Christine in cooking up a storm for

the PA Research Foundation’s inaugural

Bake Off this month.

It may have been an all-male line up for

the scone eating competition to fight

cancer – but it was the women who won

hands down at the bake off judged by

Network Ten’s Dominique Rizzo of Ready

Steady Cook.

The bake off and scone eating competition

were part of the PA Hospital’s Greatest

Morning Tea with 100 per cent of funds

raised going toward cancer research

projects funded by the PA Research

Foundation – so it was no wonder that

staff from all areas of the hospital cooked

up a storm.

PA Research Foundation Chief Executive

Officer Nicolas Allen described the

morning tea a delicious success, with all

entries cut up and sold for a gold coin

donation.

“Unfortunately cancer is a disease that will

affect two in three of us by the time we

are 85 years old,” Mr Allen said.

“The PAH is famous for its cancer

research. We are home to the first ever

cancer vaccine - Gardisil - which is now

saving millions of lives around the world.

For the record, PAH’s Ian from the

hospital’s mental health services

demolished five scones, which he cut

and covered with cream before eating, in

record time.

We think he might need counselling

before he can face another scone.

Throughout May, hospital departments

were also invited to host their own

morning teas to raise money for the PA

Research Foundation.

The department that raised the most

money was Radiation Oncology – PAH

Centre, with a total of $552.25.

They are the recipients of a Lavazza

coffee machine. Special thanks go to

the following businesses who donated

their time and prizes: Dominique Rizzo

from Pure Food Cooking, Jacqui from

Contemporary Cakes, Spirit House, Black

Pearl Epicure, Limes Hotel, Bakers

Delight.



PA Team takes on GC Marathon

Over 100 staff members and supporters

joined the PA Research Foundation’s

“Mighty PA Team” at this year’s Gold

Coast Marathon, raising over $13,000

for cancer research at the hospital.

The team was the tenth largest out of

128 teams at the July 5 marathon, with

members participating in a range of

events.

Team member Connie Freeman said

she was overwhelmed by the number of

PAH staff member who were keen to

participate.

“It highlights that many of us are faced

with the challenges of battling cancer,

either directly, by supporting loved ones,

or through nursing and patient services,”

she said.

“The Mighty PA Team participants

were given an opportunity to help

our researchers by promoting the PA

Research Foundation and raising vital

funds towards continued cancer research.”

Funds raised by the Mighty PA Team

have gone towards the purchase of a

much-needed Freeze Drier Machine used

in cancer research with the Foundation

funding the remainder of funds to

purchase this vital piece of equipment.

University of Queensland researcher,

Sherry Wu, said the machine enables

researchers to “coat” gene-silencing drugs

in a vehicle that could allow them to travel

through the immune system and “switch

off” cancer cells.

“Having this machine on the PA Hospital

campus will significantly increase our

research productivity as we will now be

able to perform this procedure on site,”

Ms Wu said.

Many participants in the marathon

achieved personal bests, smashing both

running times and fund-raising records.

The Mighty PA Team has promised it will

be back bigger and better next year.

“We’re hoping to see everyone back in

2010 and I encourage all staff, family and

friends to come on board,” Ms Freeman

said.

Thank you to Connie Freeman, Bill

Deutrom, Garrards, Bakers Delight and

Starbucks.

2 42 0 1 0 A N N U A L R E P O R T

Footy Greats Support PAH Research

They were once happy just to beat New

South Wales, but now a group of former

State of Origin superstars have another

enemy in their sights – melanoma.

Former Origin Greats (FOGS), in

conjunction with the Mardi Jackson

Foundation, have teamed up with the PA

Research Foundation to throw $70,000

at the cancer killing more Queenslanders

than anywhere else in the world.

The funds will go towards the purchase of

a Vivascope – a piece of machinery used

by PAH’s Dermatology Research Centre.

“The Vivascope is a non-invasive imaging

tool allowing doctors to see microscopic

changes in skin tissue so they can detect

early onset of melanomas as well as know

the size, location and shape of the cancer

cells,” PA Research Foundation Chief

Executive Officer Nicholas Allen said.

“It will lead to improved patient outcomes

via early, accurate detection and will also

be able to detect microscopic changes

in the skin tissue prior to clinical onset

of melanoma symptoms. “With so many

projects needing our funding, combined

with the tough economic climate of 2009,

this donation can only be described as

amazing. Everyone who has contributed

in some way should know – they will have

helped save lives.”

FOGS raised the funds in conjunction with

the Mardi Jackson Foundation from their

Annual FOGS Lunch over the past two

years.

“The earlier a melanoma is diagnosed the

better the outcome and if we can help

raise the awareness along with assisting

medical research – then that’s a good

day on the paddock,” FOGS Executive

Chairman Gene Miles said.

“Whether you play sport professionally or

for recreation, or simply go to the beach

or park with your family – we are all at risk

of melanoma.

“If a mole or a spot looks suspicious see

your family doctor – they won’t think it’s

an overreaction.”

The Vivascope imager will be used by the

Dermatology Research Centre, headed by

Professor Peter Soyer.

Thank you to the Former Origin Greats

and the Mardi Jackson Foundation.



PA Funds new hope for

Rheumatoid Arthritis patients

Thanks to loyal supporters, donors and

the Yinfoo Foundation over $100,000

was raised through the tax appeal to take

arthritis research to the next level.

Funds raised from the 2010 Tax Appeal

for RA research will purchase a vital piece

of equipment to enable Professor Ranjeny

Thomas and her team to get their clinical

trials up and running two years in advance

of schedule.

Prof. Thomas heads up a team that

specifically targets the underlying cause

of RA.

“This machine will be of critical assistance

to the team’s vaccination strategy to

prevent RA from starting in patients at

high risk of the disease.

“It has taken the team six years to get

to this point and the purchase of this

machine means that clinical trials will now

take place in the next 12 months.” Said

Prof. Thomas

Cent-a-Case Program

Australian Liquor Marketers (ALM) has

been a significant corporate supporter of

the PA Research Foundation for over 10

years.

Together in 2001, the PA Research

Foundation and ALM established the

Cent-a-Case fundraising program. This

program sees a nominated percentage

for every case of liquor sold donated

directly to the PA Research Foundation

for health research. To date, the Cent-

a-Case Program has so far raised over

$565,524.36 which is an outstanding

achievement.

ALM could not have done this without the

backing of their loyal customers who have

partaken in the Cent-a-Case program.

To date there have been over 3,300

participants so far which include liquor

stores, restaurants and hotels.

The PA Research Foundation would like

to thank ALM and their loyal customers

for their devoted support to health res-

earch and we look forward to reaching

new milestones through the Cent-a-Case

program for years to come.

If successful, this strategy should provide

long-term disease suppression with fewer

side effects than currently available drugs.

A very special thank you to the Yinfoo

family and the fundraising efforts of Erik

and his colleagues in Sydney.

2 62 0 1 0 A N N U A L R E P O R T

Workplace Giving Program Our Valued Volunteers Bequests and Free Will

The Princess Alexandra Hospital Campus

has some of Australia’s most remarkable,

world leading medical researchers. The

Workplace Giving Program is an easy and

convenient way for our supporters to help

bring their medical research to life.

More and more people are joining this

program as it is a simple, flexible and

affordable way to fund cutting edge

research. In order to find cures, treatments

and preventions for the biggest health

problems that we face as a nation.

This year, our workplace givers have

contributed a total of $21,488 to the

Foundation directly from their regular

wages as a tax deductible donation.

There are over 100 workplace givers

from the PA Hospital alone and they have

contributed $15,148 and we are confident

that this number will continue to grow.

We thank our Corporate partners who are

also regular contributors, including their

generous staff at The Southern Hotel in

Toowoomba and the Australian Leisure and

Hospitality for their contribution of $6,340

altogether.

Donations for the Workplace Giving

Program are received free of cost to the PA

Research Foundation, which means 100%

of the donations received will be used for

health and medical research.

We would like to thank our kind

hearted and dedicated volunteers who

have donated their time to support us

throughout the year. They have helped us

tremendously by assisting in fundraising

events, running of the PA Research

Foundation’s information booth and

providing us with general assistance

whenever we need it most.

We would also like to acknowledge and

thank all of the generous Suncorp Bank

and Great Brisbane Duck Race volunteers

who donated a day’s work to offer their

services at various fundraising events and

assisted with general administration duties.

As we do not always have the necessary

funds to hire permanent staff for specific

events and duties we rely heavily on the

members of the community to donate their

time to assist us in furthering our cause.

We greatly appreciate our volunteer’s

time and commitment that they have so

generously given to us.

Gifts made through a will may include

the whole of or a portion of an estate, a

specific amount of money or the residual

of the estate. These gifts may also include

real estate, stocks and shares, works of art

or any other asset.

A bequest may also be specific in its

wording nominating a research program

such as heart, prostate cancer, spinal

injury etc. All these options are covered in

bequest information which is available on

request.

Our Free Will program is available to

anyone who wishes to include the PA

Research Foundation as a beneficiary of

their estate and does not have a current

or up-to-date will. We will introduce the

Testator to a solicitor, with whom we have

an arrangement, who will take instruction

and prepare the will at no cost to the

Testator. There is no set amount for the

bequest, as a requirement to participate

in the Free Will program. Even a modest

amount will be well-received with gratitude

and sincere thanks.

For more information, contact: CEO

Nicholas Allen on (07) 3176 7301 or

[email protected]


Our Supporters

The most important breakthroughs in

medicine comes from the research done

behind the scenes carried out by our

doctors, professors and assistants.

Their research would not have made it

to the forefront of medical practice if it

wasn’t for the generous and passionate

support of our many donors. Each year we

are overwhelmed by the commitment of

our donors who provide the PA Research

Foundation with much needed funds to

assist our researchers in finding life saving

medical breakthroughs.

Over 3,801 people gave an individual

gift to the Foundation and many of these

people have supported the research work

of the foundation for many years.

On behalf of the Foundation board, the

staff team and our researchers, we wish

to extend our heart felt appreciation to the

many people who have given a donation

of all monetary value, even in times of

economic hardship. Every cent counts

when it comes to saving lives!

All donations and gifts received by the

Foundation is an investment in our future

and brings us one step closer to saving

lives.

Thank you to everyone who has lent

their support to the foundation during

the year. The more funds we raise – the

more medical research we can fund – the

nearer our researchers will get to their

next medical breakthrough.

Research today! Saving lives

tomorrow!

PA Research Foundation thanks you.

3 9

Certificate of the PA Foundation

These general purpose financial statements have been prepared pursuant to Section 62(1) of the Financial

Accountability Act 2009 (the Act), relevant sections of the Financial and Performance Management Standard

2009 and other prescribed requirements. In accordance with Section 62 (1)(b) of the Act we certify that in

our opinion:

(a) the prescribed requirements for establishing and keeping the accounts have been complied with in all

material respects; and

(b) the statements have been drawn up to present a true and fair view, in accordance with prescribed

accounting standards, of the transactions of the PA Research Foundation for the financial year ended

30 June 2010, and of the financial position of the PA Research Foundation at the end of that year.

Nicholas Allen

Chief Executive Officer

Robert Bowen

Chairman

dated this 27th day of August 2010

4 0

Independent Auditor’s Report

To the Board of the PA Foundation

Report on the Financial Report

I have audited the accompanying financial

report of PA Research Foundation which

comprises the statement of financial

position as at 30 June 2010, and the

statement of comprehensive income,

statement of changes in equity and

statement of cash flows for the year

ended on that date, a summary of

significant accounting policies, other

explanatory notes and certificates given

by the Chairman and the Chief Executive

Officer.

The Board’s Responsibility for the

Financial Report

The Board is responsible for the

preparation and fair presentation of

the financial report in accordance with

prescribed accounting requirements

identified in the Financial Accountability

Act 2009 and the Financial and

Performance Management Standard

2009, including compliance with

Australian Accounting Standards

(including the Australian Accounting

Interpretations). This responsibility

includes establishing and maintaining

internal controls relevant to the

preparation and fair presentation of the

financial report that is free from material

misstatement, whether due to fraud or

error; selecting and applying appropriate

accounting policies; and making

accounting estimates that are reasonable

in the circumstances.

Auditor’s Responsibility

My responsibility is to express an opinion

on the financial report based on the audit.

The audit was conducted in accordance

with the Auditor-General of Queensland

Auditing Standards, which incorporate

the Australian Auditing Standards. These

auditing standards require compliance

with relevant ethical requirements

relating to audit engagements and that

the audit is planned and performed to

obtain reasonable assurance whether

the financial report is free from material

misstatement.

An audit involves performing procedures

to obtain audit evidence about the

amounts and disclosures in the financial

report. The procedures selected depend

on the auditor’s judgement, including

the assessment of risks of material

misstatement in the financial report,

whether due to fraud or error. In making

those risk assessments, the auditor

considers internal control relevant

to the entity’s preparation and fair

presentation of the financial report in

order to design audit procedures that

are appropriate in the circumstances,

but not for the purpose of expressing

an opinion on the effectiveness of the

entity’s internal control, other than in

expressing an opinion on compliance with

prescribed requirements. An audit also

includes evaluating the appropriateness

of accounting policies and the

reasonableness of accounting estimates

made by the Board, as well as evaluating

the overall presentation of the financial

report including any mandatory financial

reporting requirements as approved by the

Treasurer for application in Queensland.

I believe that the audit evidence obtained

is sufficient and appropriate to provide a

basis for my audit opinion.

Independence

The Auditor-General Act 2009 promotes

the independence of the Auditor-General

and all authorised auditors. The Auditor-

General is the auditor of all Queensland

public sector entities and can only be

removed by Parliament.

4 1

The Auditor-General may conduct an audit

in any way considered appropriate and

is not subject to direction by any person

about the way in which audit powers are

to be exercised. The Auditor-General has

for the purposes of conducting an audit,

access to all documents and property

and can report to Parliament matters

which in the Auditor-General’s opinion are

significant.

Basis for Qualified Auditor’s Opinion

Bequests and donations revenue, reported

in the statement of comprehensive

income as $891,728 (2009: $933,972),

is a significant source of revenue for the

PA Research Foundation. Due to the

inherent nature of bequests and donations

received, the Foundation has determined

that it is impracticable to establish control

over the collection of these funds prior to

entry into its financial records. Accordingly,

as the evidence available to me regarding

revenue for this source was limited, my

audit procedures with respect to bequests

and donations had to be restricted to the

amounts recorded in the financial records.

I am therefore unable to, and do not,

express an opinion on the completeness

of bequests and donations revenue and

whether all donations and bequests

received by the Foundation have been

brought into account and recorded in the

financial report. My report for 2008-09

was also qualified on this basis.

Qualified Auditor’s Opinion

In accordance with s.40 of the Auditor-

General Act 2009, except for the effect

of such adjustments, if any, as may have

been determined to be necessary had

I been able to satisfy myself as to the

completeness of donation revenue, I

certify that –

(a) I have received all the information

and explanations which I have required;

and

(b) in my opinion –

(i) the prescribed requirements in

respect of the establishment and keeping

of accounts have been complied with

in all material respects, except for the

qualification noted above; and

(ii) the financial report has been

drawn up so as to present a true and fair

view, in accordance with the prescribed

accounting standards of the transactions

of the PA Research Foundation for the

financial year 1 July 2009 to 30 June

2010 and of the financial position as at

the end of that year.

G G POOLE FCPA

Auditor-General of Queensland

PA Research FoundationBuilding 1

Princess Alexandra Hospital199 Ipswich Road

Woolloongabba Qld 4102Phone: [07] 3176 2359

Fax: [07] 3176 7303

www.pafoundation.org.au

2010 annual report

Documents

medical research

research community

raisedthis research

lifethe pa research

u vvi u

lii u u

highest calibre research

nation u i